Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Matthew Steven Davids, John Francis Seymour, John F. Gerecitano, Brad S. Kahl, John M. Pagel, William G. Wierda, Mary Ann Anderson, David E. Darden, Cathy E. Nolan, Lori A. Gressick, Jianning Yang, Brenda J. Chyla, Todd A. Busman, Alison M. Graham, Elisa Cerri, Sari H. Enschede, Rod A. Humerickhouse, Andrew W Roberts
Institutions: Dana-Farber Cancer Institute, Peter MacCallum Cancer Centre, Memorial Sloan Kettering Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Washington, The University of Texas MD Anderson Cancer Center, The Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, AbbVie (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2965327629